With a rapidly changing R&D model for small biotech and large pharma/biotech companies, can a CDMO bridge the innovation gap in the area of drug development and clinical filling?
For many large pharm/biotech companies today, the acquisition of small biotech companies with promising drug candidates is an attractive option in their innovation strategy. However, high quality and safety standards are a critical precondition of this strategy while smaller biotech concentrates primarily on the current development phase of their active drug. Is a harmonization of these individual needs possible? Paul Nelles, Ph.D., vice president of Vetter Development Service responsible for Process Development explains how this leading CDMO can help bridge the gap in the latest edition of the PDA Newsbrief.